D
Don M. Benson
Researcher at Ohio State University
Publications - 222
Citations - 8928
Don M. Benson is an academic researcher from Ohio State University. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 44, co-authored 203 publications receiving 7806 citations. Previous affiliations of Don M. Benson include The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Don M. Benson,Courtney E. Bakan,Anjali Mishra,Craig C. Hofmeister,Yvonne A. Efebera,Brian Becknell,Robert A. Baiocchi,Jianying Zhang,Jianhua Yu,Megan K. Smith,Carli N Greenfield,Pierluigi Porcu,Steven M. Devine,Rinat Rotem-Yehudar,Gerard Lozanski,John C. Byrd,Michael A. Caligiuri +16 more
TL;DR: It is demonstrated that CT-011, a novel anti-PD-1 antibody, enhances humanNK-cell function against autologous, primary MM cells, seemingly through effects on NK-cell trafficking, immune complex formation with MM cells and cytotoxicity specifically toward PD-L1(+) MM tumor cells but not normal cells.
Journal ArticleDOI
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Jennifer R. Brown,John C. Byrd,Steven Coutre,Don M. Benson,Ian W. Flinn,Nina D. Wagner-Johnston,Stephen E. Spurgeon,Brad S. Kahl,Celeste M. Bello,Heather K. Webb,Dave Johnson,Sissy Peterman,Daniel Li,Thomas Jahn,Brian J. Lannutti,Roger G. Ulrich,Albert S. Yu,Langdon L. Miller,Richard R. Furman +18 more
TL;DR: The clinical utility of inhibiting the PI3Kδ pathway with idelalisib is demonstrated and the findings support the further development of idELalisib in patients with CLL.
Journal ArticleDOI
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
Flavia Pichiorri,Flavia Pichiorri,Sung Suk Suh,Sung Suk Suh,Alberto Rocci,Luciana De Luca,Cristian Taccioli,Cristian Taccioli,Ramasamy Santhanam,Wenchao Zhou,Don M. Benson,Craig Hofmainster,Hansjuerg Alder,Michela Garofalo,Gianpiero Di Leva,Stefano Volinia,Stefano Volinia,Huey Jen Lin,Danilo Perrotti,Michael Kuehl,Rami I. Aqeilan,Rami I. Aqeilan,Antonio Palumbo,Carlo M. Croce +23 more
TL;DR: Evidence is provided that miR-192, 194, and 215, which are downregulated in a subset of newly diagnosed MMs, can be transcriptionally activated by p53 and then modulate MDM2 expression, and that their downregulation plays a key role in MM development.
Journal ArticleDOI
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianhong Chu,Youcai Deng,Don M. Benson,Shun He,Tiffany Hughes,Jianying Zhang,Yong Peng,Hsiaoyin Mao,Ling Yi,Kalpana Ghoshal,Xiaoming He,Steven M. Devine,Xiaoliu Zhang,Michael A. Caligiuri,Craig C. Hofmeister,Jianhua Yu +15 more
TL;DR: CS1 represents a viable target for CAR-expressing immune cells, and autologous or allogeneic transplantation of CS1-specific CAR NK cells may be a promising strategy to treat MM.
Journal ArticleDOI
Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells
François Romagné,Pascale Andre,Pieter Spee,Stefan Zahn,Nicolas Anfossi,Laurent Gauthier,Marusca Capanni,Loredana Ruggeri,Don M. Benson,Bradley W. Blaser,Mariella Della Chiesa,Alessandro Moretta,Eric Vivier,Michael A. Caligiuri,Andrea Velardi,Nicolai Wagtmann +15 more
TL;DR: Data show that 1-7F9 confers specific, stable blockade of KIR, boosting NK-mediated killing of HLA-matched AML blasts in vitro and in vivo, providing a preclinical basis for initiating phase 1 clinical trials with this candidate therapeutic antibody.